This is an early dosing milestone with no data readout — the next catalyst will be biomarker and safety data from the 12-week controlled period. Monitor for interim data or enrollment completion updates in subsequent filings.
Price Chart
Executive Summary
Tiziana Life Sciences announced that the first three participants have been dosed in the Phase 2a Healey ALS MyMatch BANYAN clinical trial evaluating intranasal foralumab for ALS. This is an early operational milestone for a 44-patient biomarker-driven study, but no efficacy or safety data were released. The filing is a routine clinical trial progress update with no financial data or binary catalyst.
Key Facts
- First three participants dosed with intranasal foralumab in Phase 2a BANYAN ALS trial (NCT07688239)
- Trial targets 44 patients with early ALS, 3:1 randomization (active:placebo), 12-week controlled period plus 12-week extension
- Primary endpoint is safety and tolerability; secondary endpoints include Treg profiling, NfL levels, and TSPO-PET/MRI microglial activation
- Study co-funded by ALS Association; conducted at Healey & AMG Center and three additional sites
- No efficacy or safety data reported; no financial terms disclosed
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Early-stage clinical trial with no efficacy data; high risk of failure in ALS
- Small sample size (44 patients) limits statistical power for secondary endpoints
- No financial data provided; cash runway and dilution risk not addressed in this filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-103735 |
| Document: ea0306829-6k_tiziana.htm | 0001213900-26-103735 |
| Document: 0001213900-26-103735-index-headers.html | 0001213900-26-103735 |
| Document: 0001213900-26-103735-index.html | 0001213900-26-103735 |
| Document: 0001213900-26-103735.txt | 0001213900-26-103735 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (−12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (+12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8823 (−15.97%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8823 (−20.51%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8823 (−9.97%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8823 (−2.47%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8823 (−23.28%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8823 (−9.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers